https://health-infobase.canada.ca/covid-19/vaccine-safety/summary.html
Summary of this week's report updated April 1, 2022
A total of 81,736,228 vaccine doses have been administered in Canada as of March 25, 2022. Adverse events (side effects) have been reported by 43,105 people. That’s about 5 people out of every 10,000 people vaccinated who have reported 1 or more adverse events.
Of the 43,105 individual reports, 34,181 were considered non-serious (0.042% of all doses administered) and 8,924 were considered serious (0.011% of all doses administered).
Most adverse events are mild and include soreness at the site of injection or a slight fever.
Serious adverse events are rare, but do occur. They include anaphylaxis (a severe allergic reaction), which has been reported 819 times for all COVID-19 vaccines across Canada. That’s why you need to wait for a period of time after you receive a vaccination so that you can receive treatment in case of an allergic reaction.
All serious events undergo medical review to see if there are any safety issues needing further action. These processes include meeting regularly to review the data with provincial and territorial partners, the regulator, research networks and medical advisors. Any unexpected safety concerns are detected quickly and acted upon immediately.
The Public Health Agency of Canada (PHAC) and Health Canada continue to closely monitor Canadian and international reports of:
Thrombosis with thrombocytopenia syndrome following vaccination with AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine. Health Canada has updated the AstraZeneca Vaxzevria COVID-19 vaccine product monograph (PDF) and the COVISHIELD COVID-19 vaccine product monograph (PDF) to include information about these very rare events of blood clots associated with low levels of platelets following immunization. For more information, please refer to the AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine public advisory.
Summary of this week's report updated April 1, 2022
A total of 81,736,228 vaccine doses have been administered in Canada as of March 25, 2022. Adverse events (side effects) have been reported by 43,105 people. That’s about 5 people out of every 10,000 people vaccinated who have reported 1 or more adverse events.
Of the 43,105 individual reports, 34,181 were considered non-serious (0.042% of all doses administered) and 8,924 were considered serious (0.011% of all doses administered).
Most adverse events are mild and include soreness at the site of injection or a slight fever.
Serious adverse events are rare, but do occur. They include anaphylaxis (a severe allergic reaction), which has been reported 819 times for all COVID-19 vaccines across Canada. That’s why you need to wait for a period of time after you receive a vaccination so that you can receive treatment in case of an allergic reaction.
All serious events undergo medical review to see if there are any safety issues needing further action. These processes include meeting regularly to review the data with provincial and territorial partners, the regulator, research networks and medical advisors. Any unexpected safety concerns are detected quickly and acted upon immediately.
The Public Health Agency of Canada (PHAC) and Health Canada continue to closely monitor Canadian and international reports of:
Thrombosis with thrombocytopenia syndrome following vaccination with AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine. Health Canada has updated the AstraZeneca Vaxzevria COVID-19 vaccine product monograph (PDF) and the COVISHIELD COVID-19 vaccine product monograph (PDF) to include information about these very rare events of blood clots associated with low levels of platelets following immunization. For more information, please refer to the AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine public advisory.
Comment